Dec./ 2023 Cytodyn RECEIVED various iterations of potential LONG-acting therapeutics on which the company will be performing assays to determine the suitability and feasibility of LONG-acting candidates for future development...let's giddy up on those assays.
Share price reacted to the push date of Nov 11, 2024...on Arbitration.
As of end of March 2024 We have approximately 300 million shares of common stock available for issuance in new financing transactions.